Rallybio (RLYB) Competitors

Biomea Fusion (NASDAQ:BMEA) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Do insiders and institutionals hold more shares of BMEA or RLYB?

96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 27.6% of Biomea Fusion shares are held by company insiders. Comparatively, 7.4% of Rallybio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has more risk and volatility, BMEA or RLYB?

Biomea Fusion has a beta of -0.26, indicating that its stock price is 126% less volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.45, indicating that its stock price is 245% less volatile than the S&P 500.

Do analysts prefer BMEA or RLYB?

Biomea Fusion presently has a consensus target price of $24.64, indicating a potential upside of 889.41%. Rallybio has a consensus target price of $9.75, indicating a potential upside of 1,282.98%. Given Rallybio's higher probable upside, analysts plainly believe Rallybio is more favorable than Biomea Fusion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Rallybio	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Does the MarketBeat Community prefer BMEA or RLYB?

Biomea Fusion received 16 more outperform votes than Rallybio when rated by MarketBeat users. However, 78.57% of users gave Rallybio an outperform vote while only 68.97% of users gave Biomea Fusion an outperform vote.

Company	Underperform	Outperform
Biomea Fusion	Outperform Votes 60 68.97%	Underperform Votes 27 31.03%
Rallybio	Outperform Votes 44 78.57%	Underperform Votes 12 21.43%

Does the media favor BMEA or RLYB?

In the previous week, Biomea Fusion had 13 more articles in the media than Rallybio. MarketBeat recorded 16 mentions for Biomea Fusion and 3 mentions for Rallybio. Rallybio's average media sentiment score of 0.97 beat Biomea Fusion's score of 0.35 indicating that Rallybio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	1 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rallybio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is BMEA or RLYB more profitable?

Rallybio's return on equity of -77.39% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-118.90%	-93.66%
Rallybio	N/A	-77.39%	-69.33%

Which has better earnings and valuation, BMEA or RLYB?

Rallybio has higher revenue and earnings than Biomea Fusion. Biomea Fusion is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$117.25M	-$4.01	-0.62
Rallybio	$636K	46.13	-$74.56M	-$1.35	-0.52

Summary

Rallybio beats Biomea Fusion on 9 of the 17 factors compared between the two stocks.